Biosimilars in der Onkologie: bald Therapiestandard?

Biosimilars

Aus der Medizinischen Klinik mit Schwerpunkt Hämatologie und Onkologie der Medizinischen Fakultät Charité – Universitätsmedizin Berlin DISSERTATION Sequence Analysis of the NUMB Gene in Chronic Myeloid Leukaemia Patients

Better understanding of the transformation of chronic myeloid leukemia (CML) from chronic phase (CP) to the invariably fatal blast phase (BP) is of critical importance for the clinical management of patients with CML. However, the mechanisms responsible for triggering disease progression have eluded investigators’ efforts. Recently, our group verified reported data showing increased levels of M...

Pediatric Oncologic Imaging: A Key Application of Combined PET/MRI PET/MRT in der pädiatrischen Onkologie: Ein Hauptanwen- dungsgebiet

Whole-body combined PET/MR imaging has found its way into clinical practice recently and has opened up new possibilities for multiparametric morphologic and functional imaging [1]. The first PET/MR studies identified clinical applications where PET/MRI as a combined modality may have advantages over the established modalities of PET/ CT and MRI, e. g., CNS imaging [2], local prostate imaging [3...

Biosimilars in Crohn's disease.

The patent for some biological medicines used in the treatment of Crohn's disease are close to expire. Biosimilars are biologicals sufficiently similar to a biopharmaceutical already approved by a regulatory agency.1 Several companies are developing biosimilars to tumor necrosis factor and the first biosimilar submitted to the European agency for the treatment of rheumatoid arthritis was develo...

Contributions to Oncology Beiträge zur Onkologie